Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease.
Steady accumulation over the last few weeks - looking ready to run with fundamentals catalysts of PDUFA and final Phase 3 data readout for PRX-102 in April
Please don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
Protalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended to buy or sell PLX stocks.
PLX Could Claim Substantial Global Market Share In Fabry Disease.
April 27, BLA approval opportunity.
Technically, resistances in rage, 4.87 and 5.2.
Support level 4.4-4.35.
Not recommended to buy or sell PLX stocks (Very risky).
Just an Idea.
Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
PLX at its best.. 0 volume and 0 pressure upwards. Tons of downward pressure..!! Who would sell at these levels??? Short this?? Ok.. Looks bad till January?? Maybe.. we turn a corner.. Upwards.. Maybe..
As most of us know this stock doesn't deal well with resistance !! So..after poking through support I really have no idea what will happen tomorrow. I am invested in this and like many cant seem to understand why this stock has such weak abilities. Hopefully... it draws some buyers here soon and can rise above support. But it may just keep dipping lower till...
CARMIEL, Israel, August 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE
American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development,
production and commercialization of recombinant therapeutic proteins produced by its
proprietary ProCellEx® plant cell-based protein expression system, today announced completion
of the treatment...
